Headlines about OpGen (NASDAQ:OPGN) have been trending somewhat positive recently, according to Accern. Accern identifies negative and positive press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. OpGen earned a coverage optimism score of 0.19 on Accern’s scale. Accern also gave media coverage about the medical research company an impact score of 45.9353171577992 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the media headlines that may have impacted Accern Sentiment’s rankings:
- OpGen Inc (OPGN) Expected to Post Quarterly Sales of $810,000.00 (americanbankingnews.com)
- OpGen (OPGN) Set to Announce Quarterly Earnings on Wednesday (americanbankingnews.com)
- OpGen (OPGN) Cut to “Hold” at Zacks Investment Research (americanbankingnews.com)
- OpGen Announces Collaborator in Verification Study for Acuitas® Test – GlobeNewswire (press release) (globenewswire.com)
OpGen (OPGN) opened at $2.40 on Wednesday. The company has a debt-to-equity ratio of 0.03, a current ratio of 1.23 and a quick ratio of 1.13. OpGen has a 1-year low of $1.78 and a 1-year high of $31.25.
COPYRIGHT VIOLATION WARNING: “OpGen (OPGN) Earning Somewhat Positive Press Coverage, Study Shows” was originally published by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://weekherald.com/2018/03/14/opgen-opgn-given-daily-coverage-optimism-rating-of-0-19.html.
OpGen, Inc (OpGen) is a precision medicine company using molecular diagnostics and informatics to combat infectious disease. The Company is engaged in developing molecular information solutions to combat infectious disease in global healthcare settings, helping to guide clinicians with information about life threatening infections, managing patient outcomes, and the spread of infections caused by multidrug-resistant microorganisms.
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.